Markets.Businessinsider.Com·2025-11-02 13:17Core Insights - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of violations of federal securities laws related to misleading statements about the drug Efzofitimod [2][5] - The firm is encouraging investors who suffered losses exceeding $50,000 between January 16, 2025, and September 12, 2025, to discuss their legal options [1][2] Company Overview - aTyr Pharma, Inc. is facing a federal securities class action with a deadline for lead plaintiff applications set for December 8, 2025 [2] - The company’s stock experienced a significant decline of 83.25%, dropping from $6.03 on September 12, 2025, to $1.01 on September 15, 2025, following the release of disappointing clinical trial results for Efzofitimod [6] Legal Allegations - The complaint alleges that aTyr and its executives made false and misleading statements regarding the efficacy of Efzofitimod, particularly its ability to allow patients to taper off steroid usage [5] - In the EFZO-FIT study, the drug did not demonstrate a significant reduction in mean daily oral corticosteroid dose compared to placebo, with only 52.6% of patients achieving complete steroid withdrawal [6]